Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S51-S58 , 20 December 2007

The eyes in diabetes and diabetes through the eyes

  • Ilana Harman-Boehm

      Affiliations

    • Department of Internal Medicine C and the Diabetes Unit, Soroka University, Medical Center, Beer-Sheva, Israel
    • Corresponding Author InformationCorresponding author.
    • ,
  • Tomas Sosna

      Affiliations

    • Centrum Diabetologie, IKEM, Prague, Czech Republic
    • ,
  • Henrik Lund-Andersen

      Affiliations

    • University Department Herlev Hospital and Steno Diabetes Centre, Copenhagen, Denmark
    • ,
  • Massimo Porta

      Affiliations

    • University of Turin, Turin, Italy

References 

  1. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. Diabetes Care. 2004;27:S84–S87
  2. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642–652
  3. Juutilinen A, Lehto S, Ronnemma T, Pyorala K, Laakso M. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care. 2007;30:292–299
  4. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993;329:977–986
  5. UK Prospective Diabetes Study group . Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  6. UK Prospective Diabetes Study group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ. 1998;317:703–713
  7. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Opthalmologica. 2007;22:95–102
  8. Helbig H. Surgery for diabetic retinopathy. Opthalmologica. 2007;22:103–111
  9. Hall AP. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol. Pathol. 2006;134:763–775
  10. Fong DS, Aiello LP, Ferris FL, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27:2540–2553
  11. Chakrabarti S, Cukiernik M, Hileeto D. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab. Res. Rev. 2000;16:393–407
  12. Shams N, Ianchulev T. Role of vascular endothelial growth factors in ocular angiogenesis. Opthalmol. Clin. North Am. 2006;19:335–344
  13. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem. 2006;13:3307–3317
  14. Clermont AC, Bursell SE. Retinal blood flow in diabetes. Microcirculation. 2007;14:49–61
  15. Klein R, Klein BE, Moss SE, Davis MD, DeMets Dl. The Wisconsin Epidemiological Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Opthalmol. 1984;102:520–526
  16. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiological Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch. Opthalmol. 1984;102:527–532
  17. Klemp K, Larsen M, Sanders B, Vaag A, Brockhoff PB, Lund-Andersen H. Effect of short-term hyperglycemia on multifocal electroretinogram in diabetic patients without retinopathy. Ivest. Opthalmol. Vis. Sci. 2004;45:3812–3819
  18. Klemp K, Sanders b, Brockhoff PB, Vaag A, Lund-Andersen H, Larsen M. The multifocal ERG in diabetic patients without retinopathy during euglycemic clamping. Invest. Opthalmol. Vis. Sci. 2005;46:2620–2626
  19. Hara T, Inami M, Hara T. Efficacy and safety of fluorescein angiography with orally administered sodium fluorescein. Am. J. Ophthalmol. 1998;126:560–564
  20. Rivellese M, George A, Reichel E, Puliafito C. Optical coherence tomography after laser photocoagulation for clinically significant macular edema. Opthalmic. Surg. Lasers. 2000;31:192–197
  21. Clinical Practice Recommendations 2007 . Standards of Medical Care in Diabetes 2007. Diabetes Care. 2007;30:S21
  22. Liebl A, Neiss A, Spannheimer A, Reitberger U, Wagner T, Gortz A. Costs of type 2 diabetes in Germany Results of the CODE-2 stud. Dtsch Med Wochenschr. 2001;126:585–589
  23. The Diabetes Control, Complications Trial/Epidemiology of Diabetes, Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N. Engl. J. Med. 2000;342:381–389
  24. Stratton IM, Adler AI, Neil HA, Mathews DR, Manley SE, Cull CA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational trial. BMJ. 2000;321:405–412
  25. The Diabetes Control, Complications Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289–1298
  26. The Diabetes Control, Complications Trial research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–1415
  27. Zhang L, Krzentowski G, Albert A, Lefebre P. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24:1275–1279
  28. Mandarino LJ, Finlayson J, Hassell JR. High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Invest. Opthalmol. Vis. Sci. 1994;35:964–972
  29. Funatsu H, Yamashita H, Ohashi Y, Ishigaki T. Effect of rapid glycemic control on progression of diabetic retinopathy. Jpn. J. Opthalmol. 1992;36:356–367
  30. Henricsson M, Berntorp K, Fernlund P, Sundkvist G. Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes care. 2002;25:381–385
  31. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial Intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  32. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiological Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Opthalmology. 1998;105:1801–1815
  33. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiological Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Opthalmopathy. 1995;102:7–16
  34. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia. 2002;45:203–209
  35. Chaturverdi N, Sjolie AK, Sstephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes: the EUCLID Study Group; EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet. 1998;351:28–31
  36. Sjolie AK, et al. The DIbetic Candesartan Trials (DIRECT) program: baseline characteristics. J. Renin Angiotensin Aldosterone Syst. 2005;6:25–32
  37. Gupta A, Gupta V, Thapar S, Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am. J. Ophthalmol. 2004;137:675–682
  38. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 2002;56:1–11
  39. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy?. Eye. 2002;16:689–693
  40. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudates. Ophthalmology. 1991;98:1261–1265
  41. Chew EY, Klein ML, Ferris 3rd FL, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: the Early Treatment Diabetic Retinopathy Study (ETDRS) report no. 22. Arch. Ophthalmol. 1996;114:1079–1084
  42. Chueng N, Wong TY. Obesity and eye diseases. Surv. Opthalmol. 2007;52:180–195
  43. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156–163
  44. Hirai FE, Moss SE, Klein BEK, Klein R. Severe hypoglycemia and smoking in a long-term type 1 diabetic population: Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 2007;30(6):1437–1441
  45. Davis MD, Mr Fisher RE, Gangnon F, Barton LM, Aiello EY, Chew , et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic retinopathy Study report #18. Invest. Opthalmol. Vis. Sci. 1998;39:233–252
  46. Idris I, Donnelly R. Protein kinase C β inhibition: a novel therapeutic strategy for diabetic microangiopathy. Diabetes Vasc. Dis. Res. 2006;3:172–178
  47. The Eyetech Study Group . Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143–152
  48. Vinten M, Larsen M, Lund-Andersen H, Sander B, La Cour M. Short-term Effects of intravitreal triamcinalone on retinal vascular leakage and trunk vessel diameters in macular edema. Acta Ophthalmol. Scand. 2007;85:21–26
  49. Lang GE. Pharmacological treatment of diabetic retinopathy. Opthalmologica. 2007;221:112–117
  50. Soliman W, Lund-Andersen H, Larsen M. Resolution of subretinal hemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta. Opthalmol. Scand. 2006;84:707–708

PII: S0168-8227(07)00506-2

doi: 10.1016/j.diabres.2007.09.023

Diabetes Research and Clinical Practice
Volume 78, Issue 3, Supplement , Pages S51-S58 , 20 December 2007

Article Tools

* Image Usage & Resolution